ArticleJournal of thrombosis and thrombolysis2006
Monitoring anticoagulation in atrial fibrillation.
Article in Journal of thrombosis and thrombolysis, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.BMJ open · 2014Pooled it
- A retrospective analysis of systolic blood pressure time in target range among patients in coronary care unit.Scientific reports · 2025Article
- Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.Journal of thrombosis and thrombolysis · 2024Article
- Article
- Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Article
- Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.BMJ open diabetes research & care · 2017Article
- Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.BMC pharmacology & toxicology · 2015Article
- Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation.International journal of clinical pharmacy · 2015Article
- An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.Core evidence · 2015Review
- Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic.Journal of the American Heart Association · 2013Article
- An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.Core evidence · 2012Article
- Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?Journal of thrombosis and thrombolysis · 2009Review
- Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized control trials and observational studies show high-quality warfarin therapy leads to safe and effective stroke prophylaxis. In usual community practice, patient, physician and health care system factors are barriers to optimal anticoagulation. We examined the predictive relationship between inpatient and outpatient INR values in chronic non-valvular atrial fibrillation (AF) patients hospitalized for ischemic stroke (S), bleed (B) and control events (C) in usual community practice.
methodsThis nested case-control analysis identified AF patients hospitalized for S, B and C using medical and pharmacy claims spanning 4.5 years ('98-'03) and validating diagnosis with chart abstraction. AF was defined as 2 medical claims for AF >or= 42 days apart with a related prescription claim for warfarin. INRs from both outpatient and inpatient settings were used to yield a continuous history of coagulation status. Time-in-therapeutic-range (TTR) was calculated by Rosendaal's linear interpolation method. Correlation of inpatient and prognostic utility of last outpatient INRs was tested with S or B hospitalizations using univariate and multivariate logistic regression.
resultsOverall, 614 hospitalizations (means: age 73.9, CHADS(2) = 3.24; 52% male) included S (n = 98), B (n = 101) and C (n = 415) events. Average TTR was 28.6% (49.4% at INR <2.0, 21.9% at INR >3.0). First INR on admission (INR <2.0 or >3.0) was associated with S and B hospitalizations (OR-adjusted [95%CI], 1.68 [1.04-2.73] and 1.72 [1.02-2.90]), respectively. Last outpatient INR <2.0 was not associated with S (OR-adjusted [95%CI], 1.12 [0.77-1.81]), and INR >3.0 was not associated with B (OR-adjusted [95%CI], 1.25 [0.67-2.32]). Last outpatient INR measurement occurred at 28, 22 and 24 days (median; S, B & C, respectively) before hospitalization.
conclusionPatients were observed within therapeutic range less than 30% of their time on warfarin. While inpatient INRs were clearly associated with both ischemic stroke and bleed events, last outpatient INR before event was not predictive.
Indexed as
Identifiers
16622617What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.